SaRNA

TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada

Retrieved on: 
Wednesday, February 21, 2024
Research, Infectious Diseases, FDA, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Maker, Therapy, Messenger, CIPO, Vaccine, General counsel, ARCA, COVID-19, SaRNA, CNIPA, Intellectual property, Melamaravakkadu, Human

“mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.

Key Points: 
  • “mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.
  • CleanCap® technology has been used in commercially approved COVID-19 mRNA and saRNA vaccines.
  • “TriLink’s CleanCap technology is helping to bring life-saving therapeutics and vaccines to market faster,” added Kurt Oreshack, Executive Vice President & General Counsel, Maravai LifeSciences.
  • “These additional jurisdictions fortify the validity and strength of our global intellectual property.”
    Last May, TriLink launched its most robust analog to date: CleanCap® M6 .

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Technology, Biotechnology, Nanotechnology, Health, Molecule, CMO, Infection, Growth, RNA, Phospholipid, Liposome, Solubility, Organization, Absorption, Integration, Therapy, Type, Levidian Nanosystems, Small RNA, Ionization, DNA, Partnership, Creative Biolabs, CMOS, Permeability, Sphingolipid, CDMO, SaRNA, Dicarboxylic acid, Antigen, Research, Emergent, Acquisition, Lipid, Messenger, PEGylation, IBM, Geography, Risk, Fresenius (company), Fujifilm, Triglyceride, Element, MicroRNA, Acuitas Therapeutics, Vaccine

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

Retrieved on: 
Wednesday, December 6, 2023
RNA, Bladder cancer, Therapy, Clinical trial, Pharmacokinetics, BCG, SaRNA, RNAa, Patient, Safety, NMIBC, Pharmaceutical industry

JIANGSU, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a leader in the field of small activating RNA (saRNA) therapeutics, is excited to announce the submission of a clinical trial application in Australia.

Key Points: 
  • JIANGSU, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a leader in the field of small activating RNA (saRNA) therapeutics, is excited to announce the submission of a clinical trial application in Australia.
  • This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.
  • RAG-01 is recognized as the second saRNA drug worldwide to enter clinical trials and the first of its kind in China to achieve this critical milestone.
  • This development signifies a remarkable advancement in RNA-based therapeutic applications, especially in the context of challenging cancer treatments.

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
OTS, SOD1, UTRN, Heart, RNA, BMD, Myopathy, CNS, RNAa, SaRNA, Mouse, MDX, ALS, Duchenne muscular dystrophy, Lead, SCAD, Gene, DMD, Oligonucleotide, Therapy, Patient, Small RNA, Mutation, Vaccine

JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • RNAa uses short duplex RNA known as saRNA to target and ‘turn up’ transcription of endogenous genes leading to restoration of their protein function.
  • "We are very excited about the preclinical results of our utrophin activating saRNA and believe that our approach could represent an ideal therapeutic strategy that benefits all DMD and BMD patients," said Long-Cheng Li, CEO of Ractigen Therapeutics.
  • The SCADTM platform has propelled Ractigen’s leading RNA program to the clinic for the treatment of ALS patients with SOD1 mutation.

RNA Therapeutics Market Poised for Explosive Growth: Estimated Worth Exceeds $1.1 Billion by 2035, with a Remarkable 50% CAGR from 2026-2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Transfer, Gene expression, Vaccine, Infection, Investment, Vertex Pharmaceuticals, Engineering, Sarcoidosis, RNA, USD, Therapy, Safety, SaRNA, Cystic fibrosis, Attenuated vaccine, Erna, Duchenne muscular dystrophy, Recode, Messenger, Circular RNA, Small RNA, China-ASEAN Investment Cooperation Fund, RNA therapeutics, Research, Pharmaceutical industry

The "RNA Therapeutics Market and RNA Vaccines Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNA Therapeutics Market and RNA Vaccines Market" report has been added to ResearchAndMarkets.com's offering.
  • Next Generation RNA Therapeutics and Vaccines: The market is witnessing the development of next-generation RNA therapeutics and vaccines that target diseases previously considered undruggable.
  • These include modalities such as circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self-amplifying RNA (saRNA), self-amplifying mRNA (samRNA), replicating RNA (repRNA), and transfer RNA (tRNA).
  • Investment and Funding: The market has attracted substantial investments, with over $2.9 billion raised or invested in RNA therapeutics and RNA vaccines development since 2019.

VaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and Therapeutics

Retrieved on: 
Monday, June 5, 2023
Vaccine, Death, Innovate UK, Dicarboxylic acid, Therapy, Biopharmaceutical, CPI, RNA, Innovation, SaRNA, The Mindsweep: Hospitalised

CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform, and CPI, the UK’s leading independent technology innovation centre, today announce a grant of approximately £700K from Innovate UK.

Key Points: 
  • CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform, and CPI, the UK’s leading independent technology innovation centre, today announce a grant of approximately £700K from Innovate UK.
  • The grant will fund a collaborative project to advance the manufacturing process for RNA vaccines and therapeutics.
  • Dr Tim Sparey, Managing Director at VaxEquity, said: “The potential of nucleic acids as vaccines and therapeutics is only just being realised.
  • This powerful collaboration with CPI, fuelled by Innovate UK, starts with a giant step forward in scaling the manufacturing of a novel saRNA influenza vaccine.

invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Nanoparticle, Workforce Investment Act of 1998, Infection, Cancer, Temperature, Prostate, Dicarboxylic acid, Messenger, CD8, SaRNA, Sino Biopharmaceutical Limited, HKEX, Trust, HPV-positive oropharyngeal cancer, Patient, RALA, HPV, Growth, Cervical cancer, Therapy, Vaccine

invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.

Key Points: 
  • invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.
  • The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and saRNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response.
  • Prof. Helen McCarthy, Chief Executive Officer and Founder of pHion, said:
    “At pHion Therapeutics, it is our mission to pioneer next generation, first-in-class vaccines for infectious disease and oncology through stealth-like delivery of mRNA.
  • We look forward to seeing PTX_V1 reach the clinic and supporting this program into the next stages of its development.”

Self-amplifying RNA (saRNA or Replicons) Vaccines Patent Landscape Report 2023 with IP Profiles of Key Players - AlphaVax, BioNTech, Gritstone bio, GSK, Janssen, Merck - Animal Health, & Novartis - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 30, 2023
Biotechnology, Pharmaceutical, Health, Vaccine, Abstract, Database, Hepatitis, HIV, Vaccination, Gowers Review of Intellectual Property, Intellectual property, SARS-CoV-2, COVID-19, Cancer, SARS, Livestock, Srna, Research, Infection, IP, RNA, Messenger, SaRNA, Publication, Animal, Novartis, Patent, Traction, VRP, Microsoft Excel, EP, CNE, Risk management, Pharmaceutical industry, LNP

The "Self-amplifying RNA vaccines Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Self-amplifying RNA vaccines Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering.
  • Currently, there are 2 main types of mRNA vaccines: conventional non-amplifying mRNA and self-amplifying mRNA (saRNA or replicons).
  • The saRNA vaccine platform may have higher manufacturing productivity and lower cost per dose compared to mRNA vaccines.
  • Moreover, this innovative and less expensive therapy tends to apply to the veterinary area with treatments for companion animals and livestock.

Chimeron Bio Appoints Antonin (Tony) de Fougerolles to its Board of Directors

Retrieved on: 
Thursday, December 15, 2022
General Health, Health, Science, Other Science, Research, Therapy, Degenerative disease, RNA interference, Infection, Patient, SaRNA, Research, CSO, Bio, COVID-19, RNA transfection, Vaccine, Safety, RNA

Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR RNA delivery platform, announced today that Antonin (Tony) de Fougerolles had been appointed as the newest member of its Board of Directors.

Key Points: 
  • Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR RNA delivery platform, announced today that Antonin (Tony) de Fougerolles had been appointed as the newest member of its Board of Directors.
  • I cant adequately express our excitement to welcome Tony to the Chimeron Bio board, said Afshin Safavi, Ph.D., Chairman of the Board at Chimeron.
  • Chimeron Bio is actively developing next-generation saRNA-based medicines for Oncology, Infectious Diseases, and Rare Diseases.
  • Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA drugs and vaccines for various diseases.

Chimeron Bio Welcomes Kevin Heyeck as New CEO

Retrieved on: 
Tuesday, December 13, 2022
Oncology, Health, Chemicals, Plastics, Manufacturing, Genetics, Pharmaceutical, Biotechnology, Vitae, Therapy, Drug discovery, Infection, Patient, SaRNA, Research, Harvard University, Bio, COVID-19, Vaccine, Growth, Safety, RNA, Management, Pharmacopoeia

Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR RNA delivery platform, announced today that Kevin Heyeck had been named Chief Executive Officer.

Key Points: 
  • Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR RNA delivery platform, announced today that Kevin Heyeck had been named Chief Executive Officer.
  • Kevin comes to Chimeron with a long and successful track record of executive and entrepreneurial experience in life sciences.
  • In addition to joining the Chimeron Board, his board memberships include Cru Bio, UAMS Bioventures, and previously, Hibercell, Ultivue, and board observer of Iteos.
  • Kevin Heyeck possesses a rare blend of vision and operational knowledge that will support Chimeron Bio in achieving its next phase of growth.